Form 20-F

Elbit Systems Awarded a $200 Million Contract to Supply Helicopter Self-Protection Suits to a Country in Asia-Pacific

Retrieved on: 
Thursday, November 17, 2022
Securities Act of 1933, Intellectual property, Environment, Forward-looking statement, Annual report, Company, Patent, Securities Exchange Act of 1934, Program, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Form 20-F, Elbit Systems, Global health, Risk management, Thermoplastic

Forward-looking statements are based on management's current expectations, estimates, projections and assumptions about future events.

Key Points: 
  • Forward-looking statements are based on management's current expectations, estimates, projections and assumptions about future events.
  • Forwardlooking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.
  • Elbit Systems Ltd., its logo, brand, product, service and process names appearing in this Press Release are the trademarks or service marks of Elbit Systems Ltd. or its affiliated companies.
  • Reference to or use of a product, service or process other than those of Elbit Systems Ltd. does not imply recommendation, approval, affiliation or sponsorship of that product, service or process by Elbit Systems Ltd.

Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award

Retrieved on: 
Wednesday, November 16, 2022
SAN, Multiple myeloma, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, IIT, SVP, ORR, Security (finance), RRMM, Annual report, Safety, Risk, Efficiency, Industry, Society, Cancer, European Hematology Association, Technology, Patient, CD19, NASDAQ, Form 20-F, BCMA, SMART, MRD, Food, B-cell maturation antigen, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Development, Fine chemical, Vaccine, Pharmaceutical industry, Research, Graceling

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Nov. 16, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its FasTCAR Autologous CAR-T Platform was named the winner of the Biotech Innovation category of the 2022 Fierce Life Sciences Innovation Awards.

Key Points: 
  • SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Nov. 16, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its FasTCAR Autologous CAR-T Platform was named the winner of the Biotech Innovation category of the 2022 Fierce Life Sciences Innovation Awards.
  • The Fierce Life Sciences Innovation Awards identify and showcase outstanding innovation that is driving improvements and transforming the industry.
  • "We are honored that the FasTCAR next-day manufacturing platform has been recognized by the prestigious Fierce Life Sciences Innovation Awards," said Dr. Cao.
  • Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies.

Vipshop Holdings Limited to Hold Annual General Meeting on December 16, 2022

Retrieved on: 
Wednesday, November 16, 2022
People, SEC, Republic, Date, Annual, Annual report, ADSS, Mission statement, Company, Vipshop, NYSE, U.S. Securities and Exchange Commission, VIPS, Form 20-F, Security (finance)

GUANGZHOU, China, Nov. 16, 2022 /PRNewswire/ --Vipshop Holdings Limited (NYSE: VIPS), a leading online discount retailer for brands in China ("Vipshop" or the "Company"), today announced that it will hold an annual general meeting of shareholders at Vipshop Headquarters, 128 Dingxin Road, Haizhu District, Guangzhou 510220, People's Republic of China on December 16, 2022 at 11:00 a.m., Beijing time.

Key Points: 
  • GUANGZHOU, China, Nov. 16, 2022 /PRNewswire/ --Vipshop Holdings Limited (NYSE: VIPS), a leading online discount retailer for brands in China ("Vipshop" or the "Company"), today announced that it will hold an annual general meeting of shareholders at Vipshop Headquarters, 128 Dingxin Road, Haizhu District, Guangzhou 510220, People's Republic of China on December 16, 2022 at 11:00 a.m., Beijing time.
  • No proposal will be submitted for shareholder approval at the annual general meeting.
  • Instead, the annual general meeting will serve as an open forum for shareholders and beneficial owners of the Company's American depositary shares ("ADSs") to discuss Company affairs with management.
  • Beneficial owners of the Company's ADSs are welcome to attend the annual general meeting in person.

Shell begins operations at polymers plant in Pennsylvania

Retrieved on: 
Tuesday, November 15, 2022
Carbon, SEC, GAAP, Movement, Technology, Goal, Climate change, Royal Dutch Shell, Acquisition, Arrangement, Environment, Disclosure, Ohio River, Forward-looking statement, Risk, Coronavirus, Budget, Subsidiary, Natural gas, Mission statement, Education, Ownership, Phrase, Multimedia, Food packaging, Contract, Progress, U.S. Securities and Exchange Commission, COVID-19, Disease, Form 20-F, Pandemic, Intensity, Private Securities Litigation Reform Act, Shell, Building, NCF, Employment, Nationalization, Renewable energy

MONACA, Pa., Nov. 15, 2022 /PRNewswire/ --Shell Chemical Appalachia LLC, a subsidiary of Shell plc, today announced it has commenced operations of its Pennsylvania Chemical project, Shell Polymers Monaca (SPM).

Key Points: 
  • MONACA, Pa., Nov. 15, 2022 /PRNewswire/ --Shell Chemical Appalachia LLC, a subsidiary of Shell plc, today announced it has commenced operations of its Pennsylvania Chemical project, Shell Polymers Monaca (SPM).
  • The start-up of Shell Polymers Monaca represents an important step in growing Shell's chemicals business as part of its Powering Progress strategy.
  • Shell started main construction at Shell Polymers Monaca in April 2017 after taking a Final Investment Decision in June 2016.
  • ''Subsidiaries'', "Shell subsidiaries" and "Shell companies" as used in this press release referto entities over which Shell plc either directly or indirectly has control.

Shell begins operations at polymers plant in Pennsylvania

Retrieved on: 
Tuesday, November 15, 2022
Carbon, SEC, GAAP, Movement, Technology, Goal, Climate change, Royal Dutch Shell, Acquisition, Arrangement, Environment, Disclosure, Ohio River, Forward-looking statement, Risk, Coronavirus, Budget, Subsidiary, Natural gas, Mission statement, Education, Ownership, Phrase, Food packaging, Contract, Progress, U.S. Securities and Exchange Commission, COVID-19, Disease, Form 20-F, Pandemic, Intensity, Private Securities Litigation Reform Act, Shell, Building, NCF, Employment, Nationalization, Renewable energy

MONACA, Pa., Nov. 15, 2022 /PRNewswire/ --Shell Chemical Appalachia LLC, a subsidiary of Shell plc, today announced it has commenced operations of its Pennsylvania Chemical project, Shell Polymers Monaca (SPM).

Key Points: 
  • MONACA, Pa., Nov. 15, 2022 /PRNewswire/ --Shell Chemical Appalachia LLC, a subsidiary of Shell plc, today announced it has commenced operations of its Pennsylvania Chemical project, Shell Polymers Monaca (SPM).
  • The start-up of Shell Polymers Monaca represents an important step in growing Shell's chemicals business as part of its Powering Progress strategy.
  • Shell started main construction at Shell Polymers Monaca in April 2017 after taking a Final Investment Decision in June 2016.
  • ''Subsidiaries'', "Shell subsidiaries" and "Shell companies" as used in this press release referto entities over which Shell plc either directly or indirectly has control.

BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates

Retrieved on: 
Tuesday, November 15, 2022
PDAC, Multiple myeloma, SEC, U.S. Securities and Exchange Commission, Investor relations, Security (finance), G&A, Immunotherapy, GENESIS, TASE, Annual report, NDA, B cell, FDA, Risk, New Drug Application, Society, Company, TEL, Marketing, PDUFA, CXCR4, EST, Private Securities Litigation Reform Act, Patient, Webcast, COVID-19, ASH, NASDAQ, Form 20-F, Clinical trial, Pancreatic cancer, Pharmaceutical industry, BioLineRx

TEL AVIV, Israel, Nov. 15, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported third quarter financial results and recent corporate and portfolio updates.

Key Points: 
  • "Additionally, working with our collaborators, we advanced motixafortide development programs for pancreatic cancer, reflecting motixafortide's potential broad clinical utility.
  • Finally, we anticipate sharing data from the Phase 1/2a trial of our solid tumor investigational immunotherapy AGI-134 prior to year-end.
  • A dial-in replay of the call will be available untilNovember 17, 2022; please dial +1-888-295-2634 from the US or +972-3-925-5903 internationally.
  • BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis

Retrieved on: 
Tuesday, November 15, 2022
Transfer, Perception, Doctor of Philosophy, Intellectual property, Tuba City Regional Health Care Corporation, SEC, Ramot at Tel Aviv University, 3D, Technology, Allergan, MD, Patient, Colitis, Forward-looking statement, Harvard University, Annual report, City, Wyss Institute, Risk, Genetic engineering, Industry, 3D bioprinting, Company, Newsweek, 3D Systems, Ulcerative colitis, Terminology, Tissue, Sheba Medical Center, Research, Marketing, Pediatric gastroenterology, COVID-19, CEO, NASDAQ, Form 20-F, Inflammatory bowel disease, Wyss Institute for Biologically Inspired Engineering, Hospital, Drug discovery, Inflammatory Bowel Diseases, Clinical trial, AbbVie, Bio-ink, Drug development, Disease, Tel HaShomer, Public expenditure, Medical imaging, Pharmaceutical industry, Medical device, Tel Aviv University

Designed to emulate the human intestine tissue, the 3D bioprinted model will allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.

Key Points: 
  • Designed to emulate the human intestine tissue, the 3D bioprinted model will allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.
  • Kit Parker at the Wyss Institute at Harvard University, Dr. Yael Haberman from the Pediatric Gastroenterology unit of Sheba Medical Center, and CollPlant's team of scientists and engineers.
  • "We are excited to embark on this important collaboration with Tel Aviv University and Sheba Medical Center for what will represent CollPlant's strategic expansion into personalized medicine.
  • About Ramot and Tel Aviv University:
    Ramot is the technology transfer company ofTel Aviv University, one ofIsrael'sforemost research and teaching universities.

JinkoSolar's 182 mm TOPCon Module Reaches Highest Conversion Efficiency of 23.86%

Retrieved on: 
Tuesday, November 15, 2022
Energy Independence and Security Act of 2007, Technology, N, Annual report, Form 20-F, Safety, Silicon, United Kingdom, Efficiency, Industry, United Arab Emirates, Company, Terminology, JKS, NYSE, Welding, Securities Exchange Act of 1934, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Topcon, The Company, Securities Act of 1933, Solution, Renewable energy

The module adopted JinkoSolar's latest TOPCon cell technology and advanced welding and packaging technology and achieved conversion efficiency of 23.86% for the first time for 2 mm2 above large-size solar modules.

Key Points: 
  • The module adopted JinkoSolar's latest TOPCon cell technology and advanced welding and packaging technology and achieved conversion efficiency of 23.86% for the first time for 2 mm2 above large-size solar modules.
  • The advanced welding and packaging technology effectively reduces the internal resistance loss of the module, while significantly improving conversion efficiency.
  • Dr. Hao Jin, Chief Technology Officer of JinkoSolar Co., Ltd., commented, "We are pleased to make another breakthrough in module conversion efficiency, leveraging our accumulated experience and continuous efforts in N-type technology R&D and mass production.
  • JinkoSolar (NYSE: JKS) is one of the largest and most innovative solar module manufacturers in the world.

Quhuo Reported the Unaudited Financial Results for the First Half of 2022, Achieving an 89.6% Year-over-Year Increase in the Gross Profit

Retrieved on: 
Tuesday, November 15, 2022
SECURE Act of 2019, Ecosystem, Growth, Technology, U.S. Securities and Exchange Commission, EBITDA, Security (finance), Housekeeping, City, Forward-looking statement, Income, Annual report, Form 20-F, Safety, Risk, Efficiency, Industry, Travel, US, Company, Securities Exchange Act of 1934, Software as a service, Private Securities Litigation Reform Act, COVID-19, QH, NASDAQ, Entrepreneurship, Meal, Clothing, Employment, Securities Act of 1933, Solution, Film, Fine chemical, Management, Food delivery, Bank

In the first half of 2022, Quhuo maintained its strategy in 2021 of increasing revenues before enhancing profitability.

Key Points: 
  • In the first half of 2022, Quhuo maintained its strategy in 2021 of increasing revenues before enhancing profitability.
  • The overall financial performance of the first half of 2022 demonstrated the effectiveness of Quhuo's strategic planning and implementation.
  • The Company's mobility service solutions and housekeeping and accommodation solutions have also achieved excellent preperformance, achieving year-over-year increase of 32.2% and 24.7%, respectively.
  • Quhuo Limited (NASDAQ: QH) ("Quhuo" or the "Company") is a leading gig economy platform focusing on local community-centered services inChina.

Allot Board Nominates Cynthia L. Paul to Serve as a Director

Retrieved on: 
Tuesday, November 15, 2022
Princeton School of Public and International Affairs, Conexant, Head, Audit committee, Technology, U.S. Securities and Exchange Commission, Board, Security (finance), Financial compensation, TASE, Forward-looking statement, SFM, Princeton University, Annual report, Soros Fund Management, Research, Risk, Chairperson, Industry, Company, Council, Nomination, Operations research, Board of directors, Software as a service, Private Securities Litigation Reform Act, JPMorgan Chase, Annual general meeting, NASDAQ, Form 20-F, Foreign relations, International relations, Director, Statistics, DSP Group, HOD, LLC, Regulation, Special-purpose acquisition company, Solution, Management, Engineering, Allot

Ms. Paul served as Chairperson of the Board of Directors of Conexant Systems, LLC, a semiconductor company, from 2013 until 2017.

Key Points: 
  • Ms. Paul served as Chairperson of the Board of Directors of Conexant Systems, LLC, a semiconductor company, from 2013 until 2017.
  • Ms. Paul joined SFM in 2000 and served as a SFM representative for the Council on Foreign Relations and on SFM's Investment Committee.
  • Ms. Paul is an advisory board member and former board member of AlphaSense Inc., a SaaS company providing intelligent search to enterprise customers.
  • "We are extremely pleased that Ms. Paul has accepted our nomination to be appointed to the Company's Board of Directors," said Yigal Jacoby, Allot's Chairman of the Board.